RecruitingPhase 2NCT03949478

Treating Postictal Symptoms Using Ibuprofen and Nifedipine

An Initial Clinical Study to Treat Postictal Symptoms


Sponsor

University of Calgary

Enrollment

90 participants

Start Date

Feb 1, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This study will evaluate the effect of ibuprofen or nifedipine on post-seizure hypoperfusion and neurological deficits in patients with epilepsy. One group will receive ibuprofen, another will receive nifedipine, and anther placebo.


Eligibility

Min Age: 16 Years

Inclusion Criteria1

  • age \> 16 yrs, frequent seizures (\>1 per week) and cognitive ability sufficient to complete neuropsychological testing.

Exclusion Criteria1

  • multiple seizure onset zones, contraindications to CT or MR imaging, any contraindication to ibuprofen or nifedipine, as well as current or recent (\< 2 months) exposure COX-2 inhibitor or calcium channel blocker.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIbuprofen

Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.

DRUGNifedipine

Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.

DRUGPlacebo

Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.


Locations(2)

Foothills Medical Centre

Calgary, Alberta, Canada

South Health Campus

Calgary, Alberta, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03949478


Related Trials